#NSCLC Market
Explore tagged Tumblr posts
Text
Innovating Lung Cancer Care: Antibody-Drug Conjugates Lead the Way
The ENHERTU Effect: A Closer Look at the Dynamic Duo Daiichi Sankyo and AstraZeneca Taking on HER2-mutant NSCLC Lung cancer remains one of the most challenging and prevalent forms of cancer. Within this landscape, innovative treatments are offering new hope. One such breakthrough is the collaboration between Daiichi Sankyo and AstraZeneca, which brings forth ENHERTU, an Antibody-Drug Conjugate…
View On WordPress
#ADC#ADCs#Antibody-Drug Conjugates#CEACAM5#Endometrial Cancer - Pipeline Insights#Enhertu#Her2#HER3#Keytruda#Lung Cancer#Lung Cancer Treatmen#Non-Small Cell Lung Cancer#Non-Small Cell Lung Cancer Market#NSCLC#NSCLC Market#NSCLC Treatment#TROP-2
0 notes
Text
The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide.
#Global Non-Small Cell Lung Cancer (NSCLC) Market#Global Non-Small Cell Lung Cancer (NSCLC) Market News#Global Non-Small Cell Lung Cancer (NSCLC) MarketGrowth
0 notes
Text
The global Non-Small Cell Lung Cancer (NSCLC) market size is expected to reach USD 13.51 Billion in 2030 and register a revenue CAGR of 6.8% during the forecast period.
0 notes
Photo
(via Global Lung Cancer Therapeutics Market | Trends, Forecast 2024-2030)
The lung cancer therapeutics market in 2024 is dominated by the non-small cell lung cancer (NSCLC) type, which holds an estimated 85.3% share due to its high prevalence and the development of targeted therapies and immunotherapies. These advancements specifically target genetic mutations such as EGFR, ALK, and ROS1, providing personalized treatment options and improving patient outcomes with immune checkpoint inhibitors like pembrolizumab and nivolumab. Conversely, the small cell lung cancer (SCLC) segment is anticipated to register the fastest CAGR of 11% during the forecast period 2024-2030, driven by increasing smoking rates and greater awareness of available treatments. While traditional SCLC therapies primarily consist of chemotherapy and radiotherapy, the introduction of new treatments like immune checkpoint inhibitors is beginning to improve survival rates, leading to a surge in global demand for lung cancer therapeutics.
#lung cancer therapeutics#non-small cell lung cancer (nsclc)#small cell lung cancer (sclc)#cancer therapeutics
0 notes
Text
The Evolving B7-H3 Market: Size, Forecast, and Competitive Dynamics by 2034
Introduction to B7-H3 and Its Role in Oncology
B7-H3, a member of the B7 family of immune checkpoint molecules, has emerged as a promising target in cancer immunotherapy due to its significant role in immune evasion and tumor progression. Overexpressed in various cancers such as prostate cancer, non-small cell lung cancer (NSCLC), breast cancer, and pediatric tumors like neuroblastoma, B7-H3 has sparked interest for therapeutic interventions. As research into immune checkpoint inhibitors continues, the B7-H3 antibody market and B7-H3 inhibitors market size are poised for significant growth. These therapies are expected to provide new hope for patients, particularly those with cancers that exhibit resistance to conventional treatments.
B7-H3 Inhibitors Market Overview
The B7-H3 inhibitors market is emerging as a key segment within the broader immuno-oncology landscape. B7-H3-targeted therapies, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and CAR-T cell therapies, are being actively developed to treat cancers with high B7-H3 expression. The B7-H3 inhibitors market size is expected to experience substantial growth over the next decade as clinical trials progress and regulatory approvals become imminent. The market’s growth is also fueled by the increasing prevalence of cancers where B7-H3 is overexpressed, combined with a growing focus on personalized therapies that target tumor-specific biomarkers.
Target Population for B7-H3 Inhibitors
The target population for B7-H3 inhibitors consists primarily of patients diagnosed with cancers that exhibit high B7-H3 expression. Key cancer types that are likely to benefit from B7-H3 inhibitors include:
Prostate Cancer: B7-H3 is frequently overexpressed in prostate cancer, particularly in advanced stages, making it an ideal therapeutic target for mAbs and other B7-H3-targeted therapies.
Non-Small Cell Lung Cancer (NSCLC): B7-H3 has been identified as a key player in the progression of NSCLC, with high levels of expression in a significant portion of patients, making it a promising target for immunotherapy.
Breast Cancer: Certain subtypes of breast cancer, such as triple-negative breast cancer (TNBC), show elevated levels of B7-H3, and targeting this molecule may provide significant therapeutic benefits.
Pediatric Cancers: Neuroblastoma, a common pediatric cancer, is known for its overexpression of B7-H3, making it a prime target for B7-H3-directed therapies. Other pediatric cancers, such as medulloblastoma, may also benefit from these therapies.
The growing understanding of B7-H3's role in tumor progression is likely to expand the target population for these therapies, making them applicable to a broader range of cancers over time.
Competitive Landscape of the B7-H3 Inhibitors Market
The B7-H3 inhibitors market is highly competitive, with several biopharmaceutical companies actively developing innovative therapies targeting B7-H3. These therapies include monoclonal antibodies, bispecific antibodies, ADCs, and CAR-T therapies, all of which are progressing through clinical trials. Some of the key players in the B7-H3 antibody market and inhibitors landscape include:
MacroGenics: MacroGenics is at the forefront of developing enoblituzumab, a monoclonal antibody targeting B7-H3. The company is conducting clinical trials to assess the efficacy of enoblituzumab in various cancers, including prostate cancer and NSCLC.
AstraZeneca: Known for its work in antibody-drug conjugates (ADCs), AstraZeneca is advancing B7-H3-targeted ADCs to deliver potent cytotoxic drugs directly to cancer cells, offering a more precise treatment option for patients with B7-H3-positive tumors.
ImmunoGen: ImmunoGen is developing B7-H3-targeted ADCs designed to deliver toxic payloads specifically to cancer cells expressing B7-H3. Their approach aims to improve treatment outcomes while minimizing off-target effects.
Novartis: Novartis is pursuing CAR-T cell therapies that target B7-H3, particularly in pediatric cancers like neuroblastoma, which is known for its high B7-H3 expression.
Other Emerging Players: Other companies such as GSK, Bristol Myers Squibb, and AbbVie are also exploring B7-H3 inhibitors and therapies, positioning themselves as key competitors in this growing market.
As the clinical trials for these therapies progress and more results become available, the competitive landscape will continue to evolve, with collaborations and partnerships likely to play a significant role in the development of B7-H3-targeted treatments.
B7-H3 Market Forecast to 2034
The B7-H3 market is projected to experience rapid growth through 2034, driven by advances in drug development, a deeper understanding of tumor biology, and increasing investment in oncology research. The B7-H3 inhibitors market size is expected to reach multi-billion-dollar valuations by the early 2030s, as several promising B7-H3-targeted therapies are expected to gain regulatory approval in key markets like the U.S., Europe, and Asia-Pacific.
Several factors are driving this growth:
Rising Cancer Incidence: The global rise in cancer incidence, particularly in prostate, lung, and breast cancers, is expected to increase demand for targeted therapies like B7-H3 inhibitors.
Improved Patient Stratification: Biomarker-based approaches are improving the ability to identify patients most likely to benefit from B7-H3-targeted therapies, driving adoption of these treatments.
Combination Therapies: B7-H3 inhibitors are being evaluated in combination with other immunotherapies, such as PD-1/PD-L1 inhibitors, to enhance treatment efficacy and overcome resistance mechanisms in tumors.
Regulatory Approvals: The approval of B7-H3 inhibitors by regulatory agencies such as the U.S. FDA and European Medicines Agency (EMA) will accelerate market growth, especially as clinical trial results continue to support their safety and efficacy.
Conclusion
The B7-H3 inhibitors market is positioned for significant expansion, with promising therapies on the horizon for a variety of cancers. As the understanding of B7-H3’s role in immune evasion and tumor progression deepens, the market will see an increasing number of targeted therapies moving through clinical trials and toward regulatory approval. With a growing target population, robust competition, and increasing investment in cancer immunotherapy, the B7-H3 market size is expected to experience substantial growth, reaching new heights by 2034. The future of B7-H3-targeted therapies holds great promise for improving cancer care and outcomes for patients worldwide.
Latest Reports
Contraceptive Devices Market | Crohns Disease Cd Market | Cutaneous T-cell Lymphoma Market | Diabetic Neuropathy Market | Ehlers-danlos Syndrome Market | Encephalitis Market | Epidermolysis Bullosa Market | Familial Amyloid Polyneuropathy Market | Healthcare Competitive Benchmarking | Hepatic Encephalopathy Epidemiology Forecast | Hepatitis B Virus Market | Hepatitis D Market | Hereditary Spastic Paraplegias Market | Hpv-induced Cancers Market | Human Papillomavirus Positive Cancer Market | Hyperkalemia Market | Nontuberculous Mycobacteria Infection Market | Post-bariatric Hypoglycemia Market | Postsurgical Pain Market | Primary Progressive Multiple Sclerosis Ppms Market | Surgical Stapling Devices Market | Vascular Access Devices Market | Vascular Dementia Market | Wound Closure Devices Market | Xerostomia Market
#B7-H3#B7-H3 Market#B7-H3 Forecast#B7-H3 Companies#B7-H3 Therapies#B7-H3 Epidemiology#B7-H3 Pipeline#B7-H3 Market Size#B7-H3 Market Trends
0 notes
Text
0 notes
Text
0 notes
Text
Atezolizumab Injection : A Guide to Tecentriq and Its Uses in India
In recent years, immunotherapy has emerged as a groundbreaking approach in cancer treatment, offering renewed hope for patients facing difficult-to-treat cancers. One such immunotherapy drug is Atezolizumab, marketed under the brand name Tecentriq. This drug has shown promising results in treating a variety of cancers, including lung cancer, bladder cancer, and specific forms of breast cancer. However, like many innovative treatments, the cost can be a concern, particularly in India. In this post, we will explore the atezolizumab injection price, its uses, and what patients can expect when considering Tecentriq as part of their cancer treatment plan.
Atezolizumab – Uses & Introduction
Atezolizumab is a cancer immunotherapy drug classified as a PD-L1 inhibitor. It enhances the immune system’s ability to recognize and destroy cancer cells. In normal conditions, cancer cells evade the immune system by producing a protein called PD-L1, which essentially “turns off” the body’s immune response against them. Atezolizumab blocks this PD-L1 protein, allowing the immune system to detect and attack cancer cells more effectively.
Atezolizumab injection is used to treat various cancers, including:
Non-small cell lung cancer (NSCLC)
Small cell lung cancer (SCLC)
Urothelial carcinoma (bladder cancer)
Triple-negative breast cancer (TNBC)
Hepatocellular carcinoma (liver cancer)
It is often prescribed for advanced-stage cancers or when the cancer has metastasized (spread to other parts of the body). Atezolizumab is typically administered alongside chemotherapy or other cancer treatments, depending on the type and stage of the cancer.
How Does Atezolizumab Work? The Mechanism of Action
Understanding how Atezolizumab works can provide patients with a clearer perspective on its role in cancer treatment. Under normal circumstances, the immune system attacks anything recognized as harmful, including cancer cells. However, tumors can avoid immune detection by producing PD-L1, which effectively shuts down the immune response.
Atezolizumab interrupts this process by binding to PD-L1 and preventing it from interacting with the PD-1 receptor on immune cells. This restores the immune system’s ability to recognize and fight cancer cells, allowing for a more targeted and effective treatment. As a result, many patients experience improved outcomes, particularly in advanced cancers.
Tecentriq 1200mg Injection Price in India
Like most immunotherapy drugs, the cost of Atezolizumab is significant, and it’s important to consider the Tecentriq 1200mg injection price when planning treatment. In India, the price typically ranges from ₹2.5 lakh to ₹3.5 lakh per dose, depending on the healthcare provider, location, and any applicable discounts or assistance programs.
The high cost reflects the advanced nature of the drug’s formulation and the research behind its development. For many patients, Atezolizumab requires multiple doses over a period of months, depending on the cancer type and stage, which can substantially increase the total treatment cost.
Atezolizumab Injection Price: What Influences the Cost?
Several factors contribute to the atezolizumab injection price in India:
Manufacturer: Tecentriq is produced by Roche, a global pharmaceutical leader, and the cost reflects the investment in research, clinical trials, and obtaining regulatory approvals.
Healthcare Facility: The cost can vary depending on whether treatment is administered in private hospitals, public healthcare facilities, or specialized cancer clinics.
Insurance Coverage: Patients with comprehensive insurance may have some of the costs covered, though policies can differ widely, so it’s important to confirm coverage specifics.
Number of Doses: Treatment duration and the number of doses required depend on the type of cancer and its progression, directly impacting overall costs.
Although the atezolizumab injection price can be high, it offers life-extending benefits for many cancer patients, making the investment in treatment worthwhile for eligible individuals.
Financial Assistance and Support Options
Given the high Tecentriq 1200mg injection price, financial assistance programs are available to help patients manage treatment costs. These include:
Insurance: Health insurance providers may offer partial or full coverage for immunotherapy treatments like Atezolizumab. Check with your insurance provider to confirm coverage.
Pharmaceutical Assistance Programs: Roche offers patient support programs that can reduce the out-of-pocket costs for Tecentriq. For those in need of financial aid, Medlama can assist in connecting patients with such programs to obtain the best possible price for Atezolizumab.
Government Health Schemes: Programs like Ayushman Bharat offer affordable cancer treatment for eligible patients in India, providing further financial support.
Non-Profit Organizations: Organizations like the Indian Cancer Society and CanSupport provide financial assistance to cancer patients who cannot afford treatment costs.
Exploring these options can significantly ease the financial burden of cancer treatment.
What to Expect During Atezolizumab Treatment
Atezolizumab is administered as an IV infusion, typically every two to four weeks, depending on the patient’s specific treatment plan. Each session lasts about 30 to 60 minutes.
Common side effects include fatigue, nausea, and reduced appetite. Some patients may also experience immune-related side effects, such as inflammation in organs like the lungs, liver, or intestines. Close monitoring by a healthcare team is essential to manage these side effects and ensure treatment efficacy.
Conclusion: Balancing Cost and Treatment Effectiveness
Atezolizumab, sold under the brand name Tecentriq, represents a breakthrough in cancer treatment, offering new hope for patients with advanced or difficult-to-treat cancers. However, the atezolizumab injection price in India, ranging between ₹2.5 lakh and ₹3.5 lakh per dose, can be a significant financial concern.
For those exploring this treatment, it’s essential to explore available financial assistance programs. Consult with your healthcare provider or pharmacy counselor at Medlama to find the best possible offers and support options, ensuring you receive the treatment without an overwhelming financial burden.
Source URL- https://medlama.com/product/tecentriq/
0 notes
Text
Future and Growth of Tissue Diagnostics Market by 2030
Tissue Diagnostics Market
The global tissue diagnostics market size was estimated at USD 5.19 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.15% from 2023 to 2030.
Tissue diagnostics remains a gold standard for cancer diagnosis as these technologies capture the anatomy of tumors. With rising incidences of cancer, the tissue diagnostics industry witnesses high demand with significant growth opportunities over the forecast period. The impact of COVID-19 on the tissue diagnostics industry has been significant. During the pandemic, there was a slowdown in routine medical procedures, including diagnostic testing, as healthcare resources were redirected toward managing the virus.
Gather more insights about the market drivers, restrains and growth of the Tissue Diagnostics Market
The pandemic led to a temporary decline in the demand for tissue diagnostics products and services. However, as the situation improved and healthcare systems adapted to the new normal, the market began to recover. The need for accurate diagnosis and monitoring of various diseases, including cancer, remained high, driving the demand for tissue diagnostics in the post-pandemic period.
Cancer incidences are increasing dramatically, which has caused a paradigm change in anatomic pathology. This, in turn, is contributing to the clinical pathology field's continued growth. Digitalization of diagnosis methods, increased use of liquid biopsy for cancer detection, and a continuous convergence of anatomical and molecular pathology. The importance of integrated bioinformatics and analyses increases as computational pathology gains momentum. Over the past two decades, the tissue diagnostics industry has changed as more advanced equipment has become available, making life easier for pathologists and physicians.
For instance, in May 2021, to increase the availability of precision medication for lung cancer, QIAGEN released its first FDA-approved tissue companion diagnostic to detect the KRAS G12C mutation in NSCLC tumors. The Rotor-Gene Q MDx instrument, a part of the modular QIAsymphony family of automation solutions, is used with the real-time qualitative PCR kit. This tool builds on QIAGEN's nine years of experience in researching and marketing KRAS CDx tests.
Globally, more than 14 million individuals are diagnosed with cancer each year, and by 2030, that figure is projected to increase to more than 21 million. Major market participants are introducing new cancer diagnosis products. For instance, Roche introduced its innovative BenchMark ULTRA PLUS system for cancer diagnostics in June 2022, enabling prompt, precise patient care. Pathologists can deliver high-quality, time-sensitive results to doctors and patients due to the BenchMark ULTRA PLUS tissue staining system's improved workflow, testing efficiency, and environmentally sustainable features.
Considering the rising worldwide cancer burden, various technologies, and improvements in tissue diagnostics (TDx) will increase pathology efficiency, which is essential for better cancer therapy and diagnosis. For example, Ibex Medical Analytics, the industry pioneer in AI-powered cancer diagnoses, and Alverno Laboratories announced a new deal in March 2023. It aims to expand the implementation of Ibex's Galen suite of Artificial Intelligence solutions to the entire Alverno network across Indiana and Illinois. The deployment comprises AI-powered solutions for cancer diagnosis across numerous tissue types and will help Alverno pathologists in providing the highest quality care for their patients.
A rise in the adoption rate of automated tissue-based diagnostic systems by research institutes enables them to diagnose tumors faster. In January 2023, MilliporeSigma announced its plans to expand its portfolio of antibodies for tissue diagnostics to help improve the classification of gliomas and other tumors in the nervous systems. Such R&D investments will ensure the market continues to grow.
Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.
The global hematologic malignancies market size was valued at USD 67.23 billion in 2023 and is projected to grow at a CAGR of 8.0% from 2024 to 2030.
The global precision diagnostics market size was estimated at USD 15.60 billion in 2023 and is projected to grow at a CAGR of 18.4% from 2024 to 2030.
Key Companies & Market Share Insights
The tissue diagnostics market is fragmented due to the presence of several medium-to-small and large participants in the marketspace. The advent of novel diagnostic models by key players to enhance their technology portfolio has raised competitiveness in the market. For instance, in June 2022, Roche announced the launch of VENTANA DP 600 - the next-generation slide scanner. This high-capacity slide scanner provides the pathology lab with workflow flexibility and ease of use while producing stained histology slides with exceptional image quality from tissue samples. Some prominent players in the global tissue diagnostics market include:
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Thermo Fisher Scientific Inc.
Siemens
Danaher
bioMérieux SA
QIAGEN
BD
Merck KGaA
GE Healthcare
BioGenex
Cell Signaling Technology, Inc.
Bio SB
DiaGenic ASA
Agilent Technologies
Order a free sample PDF of the Tissue Diagnostics Market Intelligence Study, published by Grand View Research.
0 notes
Text
Understanding c-MET Non-Small Cell Lung Cancer Market: Causes, Symptoms, Diagnosis, and Treatment Options
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 85% of all lung cancer cases. Within the realm of NSCLC, c-MET-positive tumors represent a significant subset associated with specific molecular and clinical characteristics. This article provides a detailed exploration of c-MET-positive NSCLC, including its causes, signs and symptoms, diagnostic approaches, and treatment options, drawing insights from the latest market research and developments.
c-MET, also known as hepatocyte growth factor receptor (HGFR), is a proto-oncogene that plays a crucial role in cell growth, migration, and invasion. In NSCLC, the c-MET gene can become dysregulated, leading to aberrant signaling pathways that promote tumor growth and metastasis. Overexpression or mutation of the c-MET gene has been implicated in aggressive tumor behavior and resistance to standard therapies.
c-MET-positive NSCLC often presents with distinct clinical features and may require specialized treatment approaches to effectively manage the disease. Identifying and targeting c-MET alterations is essential for optimizing therapeutic strategies and improving patient outcomes.
Causes of c-MET Non-Small Cell Lung Cancer
The exact causes of c-MET-positive NSCLC are multifaceted and involve a combination of genetic and environmental factors:
1. Genetic Mutations: Mutations or amplifications in the c-MET gene can lead to the overexpression of the c-MET protein, driving tumor growth and progression. These genetic alterations can result from inherited genetic predispositions or acquired mutations.
2. Environmental Factors: Exposure to carcinogens, such as tobacco smoke, asbestos, and environmental pollutants, is a well-established risk factor for lung cancer. These environmental factors can contribute to the development of genetic mutations and aberrant signaling pathways, including those involving c-MET.
3. Preexisting Lung Conditions: Chronic lung conditions, such as chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis, can increase the risk of developing lung cancer. These conditions may contribute to the dysregulation of c-MET signaling.
4. Family History: A family history of lung cancer or other cancers can increase the risk of developing NSCLC, including c-MET-positive tumors. Genetic predisposition and familial cancer syndromes may play a role in c-MET dysregulation.
Signs and Symptoms
The symptoms of c-MET-positive NSCLC are similar to those of other NSCLC subtypes, though the presence of c-MET alterations may influence the disease's clinical behavior. Common signs and symptoms include:
1. Persistent Cough: A chronic cough that does not improve with treatment may be an early sign of lung cancer. In c-MET-positive NSCLC, the cough may become more severe and persistent.
2. Shortness of Breath: Difficulty breathing or shortness of breath can occur as the tumor grows and obstructs the airways or lung tissue.
3. Chest Pain: Patients may experience localized chest pain or discomfort, which can be caused by the tumor's growth or invasion into surrounding tissues.
4. Hemoptysis: Coughing up blood or blood-streaked sputum may indicate advanced disease or tumor invasion.
5. Weight Loss and Fatigue: Unexplained weight loss and persistent fatigue are common systemic symptoms of cancer, including c-MET-positive NSCLC.
6. Recurrent Infections: Frequent respiratory infections or pneumonia may occur as the tumor obstructs or damages the lung tissue.
To know more about c-MET NSCLC Treatment market, visit: https://www.delveinsight.com/report-store/cmet-mnsclc-market
Diagnosis of c-MET Non-Small Cell Lung Cancer
The diagnosis of c-MET-positive NSCLC involves a combination of imaging studies, biopsy, and molecular testing:
1. Imaging Studies:
- Chest X-Ray: A preliminary imaging test that can reveal abnormalities in the lungs, such as masses or nodules.
- Computed Tomography (CT) Scan: Provides detailed cross-sectional images of the chest and can help identify the size, location, and extent of the tumor. CT scans are often used for staging and assessing tumor spread.
- Positron Emission Tomography (PET) Scan: PET scans can detect areas of increased metabolic activity associated with cancer, aiding in the detection of metastases.
2. Biopsy:
- Bronchoscopy: A procedure in which a flexible tube with a camera is inserted through the airways to obtain tissue samples from the tumor.
- Needle Biopsy: A needle is used to extract tissue samples from the tumor, often guided by imaging techniques.
3. Molecular Testing:
- c-MET Gene Testing: Identifies mutations or amplifications in the c-MET gene that are associated with tumor growth and progression. This testing is essential for determining the appropriate targeted therapy.
- Next-Generation Sequencing (NGS): Provides comprehensive genetic analysis to identify various mutations and alterations in the tumor, including c-MET.
Treatment Options for c-MET Non-Small Cell Lung Cancer
Treatment for c-MET-positive NSCLC often involves a combination of standard therapies and targeted approaches to address the specific molecular characteristics of the tumor:
1. Surgery: Surgical resection is often the first-line treatment for localized NSCLC. The goal is to remove the tumor and affected lung tissue. However, surgery may not be suitable for all patients, particularly those with advanced or metastatic disease.
2. Radiation Therapy: Radiation therapy uses high-energy rays to target and destroy cancer cells. It may be used as an adjuvant treatment following surgery or as a primary treatment for inoperable tumors.
3. Chemotherapy: Systemic chemotherapy involves the use of drugs to kill cancer cells throughout the body. It is often used for advanced or metastatic NSCLC and may be combined with other treatments.
4. Targeted Therapy:
- c-MET Inhibitors: Specific drugs targeting the c-MET pathway, such as crizotinib, cabozantinib, and tepotinib, are used to inhibit abnormal c-MET signaling and reduce tumor growth. These therapies are tailored to patients with c-MET gene mutations or amplifications.
- Combination Therapies: Combining c-MET inhibitors with other targeted agents or immunotherapies may enhance treatment efficacy and overcome resistance.
5. Immunotherapy: Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, can help stimulate the immune system to recognize and attack cancer cells. While not specific to c-MET, these therapies may be used in conjunction with targeted treatments.
6. Clinical Trials: Participation in clinical trials may provide access to new and experimental treatments that are not yet widely available. Clinical trials are essential for advancing treatment options and improving outcomes for patients with c-MET-positive NSCLC.
Market Insights
The market for c-MET-positive NSCLC treatments reflects the growing demand for targeted therapies and advancements in personalized medicine:
- Market Size and Growth: The global market for c-MET-positive NSCLC treatments is expanding, driven by increasing prevalence, advances in molecular diagnostics, and the development of targeted therapies. Key market segments include pharmaceuticals, diagnostic tools, and personalized treatment solutions.
- Key Players: Leading companies involved in the c-MET NSCLC market include:
- Pfizer Inc.: Known for its development of targeted therapies and involvement in the treatment of lung cancer.
- Roche Holdings: Engaged in the development of targeted therapies and molecular diagnostics for NSCLC.
- Novartis Pharmaceuticals: Focuses on innovative treatments and research in oncology, including c-MET-targeted therapies.
- AstraZeneca: Contributes to research and development of targeted and combination therapies for lung cancer.
- Research and Development: Ongoing research aims to improve understanding of c-MET signaling, develop new targeted therapies, and enhance diagnostic capabilities. Innovations in drug development and molecular diagnostics are contributing to better management and treatment outcomes for patients with c-MET-positive NSCLC.
c-MET-positive NSCLC represents a significant subset of non-small cell lung cancer with distinct molecular and clinical characteristics. Understanding the causes, symptoms, and treatment options is crucial for effective management of this challenging condition. Advances in targeted therapies and molecular diagnostics offer hope for improved outcomes and personalized treatment strategies. The growing market for c-MET NSCLC treatments underscores the importance of continued research and innovation in addressing this complex and impactful form of lung cancer.
Download report @ https://www.delveinsight.com/sample-request/cmet-mnsclc-market
0 notes
Text
Exploring the Versatile Uses of Liquid Biopsies in Modern Medicine
In recent years, liquid biopsy has emerged as a groundbreaking tool in the field of medicine, offering a less invasive alternative to traditional tissue biopsies. This innovative technique, which involves the analysis of biomarkers in bodily fluids such as blood, urine, or saliva, is revolutionizing the way we diagnose, monitor, and treat various diseases. Let’s delve into the versatile uses of liquid biopsies and how they are transforming healthcare.
Download PDF Brochure
1. Cancer Detection and Diagnosis
One of the most significant uses of liquid biopsy is in the early detection and diagnosis of cancer. Traditional tissue biopsies can be invasive, painful, and sometimes risky. In contrast, liquid biopsies offer a non-invasive way to detect cancerous cells or DNA fragments (circulating tumor DNA or ctDNA) in the bloodstream. This allows for the identification of cancer at an earlier stage, often before symptoms appear, which can lead to more effective treatment options and improved patient outcomes.
2. Monitoring Treatment Response
Liquid biopsies are also invaluable in monitoring how well a patient is responding to cancer treatment. By regularly analyzing the ctDNA levels in a patient’s blood, doctors can determine whether a treatment is effectively targeting the tumor. If ctDNA levels decrease, it indicates that the treatment is working. Conversely, an increase may suggest that the cancer is not responding to the therapy, prompting a change in the treatment plan.
3. Detecting Cancer Recurrence
For cancer survivors, the fear of recurrence is ever-present. Liquid biopsy offers a way to monitor patients after treatment to detect any signs of cancer returning. By analyzing blood samples for ctDNA, doctors can identify a recurrence long before it would be detectable through imaging or other traditional methods. Early detection of recurrence allows for prompt intervention, potentially improving the chances of successful treatment.
4. Identifying Genetic Mutations
Liquid biopsy is not limited to detecting cancer alone. It can also be used to identify specific genetic mutations that may be present in a patient’s tumor. This information is crucial for personalized medicine, where treatments are tailored to the individual based on the genetic profile of their disease. For example, in cases of non-small cell lung cancer (NSCLC), liquid biopsy can detect mutations in the EGFR gene, which can guide the use of targeted therapies.
Request Sample Pages
5. Non-Cancer Applications
While liquid biopsy is most commonly associated with cancer, its applications extend beyond oncology. Researchers are exploring its use in detecting and monitoring other conditions, such as cardiovascular diseases, infectious diseases, and prenatal testing. For instance, liquid biopsy can detect fetal DNA in a pregnant woman’s blood, providing a non-invasive method for prenatal genetic testing.
6. Advancing Research and Drug Development
Liquid biopsies are also playing a pivotal role in research and drug development. Pharmaceutical companies use liquid biopsy to identify biomarkers and genetic mutations that are critical in the development of targeted therapies. This not only speeds up the drug development process but also enhances the precision of clinical trials by selecting patients who are more likely to benefit from a specific treatment.
Conclusion
The uses of liquid biopsy are vast and varied, making it a powerful tool in modern medicine. From early cancer detection to personalized treatment plans and beyond, liquid biopsy is transforming how we approach disease management and treatment. As research and technology continue to advance, the potential of liquid biopsy will only grow, offering hope for earlier diagnoses, more effective treatments, and better patient outcomes across a range of medical conditions.
Content Source:
https://www.prnewswire.com/news-releases/liquid-biopsy-market-worth-11-3-billion--marketsandmarkets-302139796.htmlhttps://www.globenewswire.com/en/news-release/2024/05/27/2888486/0/en/Liquid-Biopsy-Market-is-Expected-to-Reach-11-3-billion-MarketsandMarkets.html
0 notes
Text
Tissue Diagnostics Market Business Growth, Opportunities and Forecast, 2030
The global tissue diagnostics market size was estimated at USD 5.19 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.15% from 2023 to 2030.
Tissue diagnostics remains a gold standard for cancer diagnosis as these technologies capture the anatomy of tumors. With rising incidences of cancer, the tissue diagnostics industry witnesses high demand with significant growth opportunities over the forecast period. The impact of COVID-19 on the tissue diagnostics industry has been significant. During the pandemic, there was a slowdown in routine medical procedures, including diagnostic testing, as healthcare resources were redirected toward managing the virus.
Gather more insights about the market drivers, restrains and growth of the Tissue Diagnostics Market
The pandemic led to a temporary decline in the demand for tissue diagnostics products and services. However, as the situation improved and healthcare systems adapted to the new normal, the market began to recover. The need for accurate diagnosis and monitoring of various diseases, including cancer, remained high, driving the demand for tissue diagnostics in the post-pandemic period.
Cancer incidences are increasing dramatically, which has caused a paradigm change in anatomic pathology. This, in turn, is contributing to the clinical pathology field's continued growth. Digitalization of diagnosis methods, increased use of liquid biopsy for cancer detection, and a continuous convergence of anatomical and molecular pathology. The importance of integrated bioinformatics and analyses increases as computational pathology gains momentum. Over the past two decades, the tissue diagnostics industry has changed as more advanced equipment has become available, making life easier for pathologists and physicians.
For instance, in May 2021, to increase the availability of precision medication for lung cancer, QIAGEN released its first FDA-approved tissue companion diagnostic to detect the KRAS G12C mutation in NSCLC tumors. The Rotor-Gene Q MDx instrument, a part of the modular QIAsymphony family of automation solutions, is used with the real-time qualitative PCR kit. This tool builds on QIAGEN's nine years of experience in researching and marketing KRAS CDx tests.
Globally, more than 14 million individuals are diagnosed with cancer each year, and by 2030, that figure is projected to increase to more than 21 million. Major market participants are introducing new cancer diagnosis products. For instance, Roche introduced its innovative BenchMark ULTRA PLUS system for cancer diagnostics in June 2022, enabling prompt, precise patient care. Pathologists can deliver high-quality, time-sensitive results to doctors and patients due to the BenchMark ULTRA PLUS tissue staining system's improved workflow, testing efficiency, and environmentally sustainable features.
Considering the rising worldwide cancer burden, various technologies, and improvements in tissue diagnostics (TDx) will increase pathology efficiency, which is essential for better cancer therapy and diagnosis. For example, Ibex Medical Analytics, the industry pioneer in AI-powered cancer diagnoses, and Alverno Laboratories announced a new deal in March 2023. It aims to expand the implementation of Ibex's Galen suite of Artificial Intelligence solutions to the entire Alverno network across Indiana and Illinois. The deployment comprises AI-powered solutions for cancer diagnosis across numerous tissue types and will help Alverno pathologists in providing the highest quality care for their patients.
A rise in the adoption rate of automated tissue-based diagnostic systems by research institutes enables them to diagnose tumors faster. In January 2023, MilliporeSigma announced its plans to expand its portfolio of antibodies for tissue diagnostics to help improve the classification of gliomas and other tumors in the nervous systems. Such R&D investments will ensure the market continues to grow.
Tissue Diagnostic Market Segmentation
Grand View Research has segmented the global tissue diagnostics market report based on technology, application, end-use, and region:
Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Immunohistochemistry
o Instruments
o Slide Staining Systems
o Tissue Microarrays
o Tissue Processing Systems
o Slide Scanners
o Other Products
o Consumables
o Antibodies
o Reagents
o Kits
• In Situ Hybridization
o Instruments
o Consumables
o Software
• Primary & Special Staining
• Digital Pathology and Workflow
o Whole Slide Imaging
o Image Analysis Informatics
o Information Management System Storage & Communication
• Anatomic Pathology
o Instruments
o Microtomes & Cryostat Microtomes
o Tissue Processors
o Automatic Strainers
o Other Products
o Consumables
o Reagents & Antibodies
o Probes & Kits
o Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
• Breast Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer
• Gastric Cancer
• Other Cancers
End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Research Laboratories
• Pharmaceutical Organizations
• Contract Research Organizations (CROs)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o Spain
o France
o Italy
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o South Korea
o Singapore
o Australia
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.
• The global hematologic malignancies market size was valued at USD 67.23 billion in 2023 and is projected to grow at a CAGR of 8.0% from 2024 to 2030.
• The global precision diagnostics market size was estimated at USD 15.60 billion in 2023 and is projected to grow at a CAGR of 18.4% from 2024 to 2030.
Key Companies & Market Share Insights
The tissue diagnostics market is fragmented due to the presence of several medium-to-small and large participants in the marketspace. The advent of novel diagnostic models by key players to enhance their technology portfolio has raised competitiveness in the market. For instance, in June 2022, Roche announced the launch of VENTANA DP 600 - the next-generation slide scanner. This high-capacity slide scanner provides the pathology lab with workflow flexibility and ease of use while producing stained histology slides with exceptional image quality from tissue samples. Some prominent players in the global tissue diagnostics market include:
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Siemens
• Danaher
• bioMérieux SA
• QIAGEN
• BD
• Merck KGaA
• GE Healthcare
• BioGenex
• Cell Signaling Technology, Inc.
• Bio SB
• DiaGenic ASA
• Agilent Technologies
Order a free sample PDF of the Tissue Diagnostics Market Intelligence Study, published by Grand View Research.
#Tissue Diagnostics Market#Tissue Diagnostics Industry#Tissue Diagnostics Market size#Tissue Diagnostics Market share#Tissue Diagnostics Market analysis
0 notes
Text
Avelumab Market Trends Analysis: Research Methodologies and Growth Opportunities until 2032
Avelumab Market Introduction:
Adhering to stringent rules, possessing substantial clinical trial evidence, and being committed to patient safety are considered indicators of quality in the Avelumab market. Manufacturers and other industry players place a great value on quality control processes to ensure the drug is uniform and effective. Furthermore, quality includes ongoing R&D efforts aimed at expanding Avelumab's therapeutic applications and exploring potential combinations with other medications to improve therapeutic outcomes.
Get a sample copy of this report:https://wemarketresearch.com/reports/request-free-sample-pdf/avelumab-market/1495
Avelumab Market Size And Forecast
The market is comprehensively evaluated for the predicted period in the Global Avelumab Market research. A review of the trends and other variables that are significantly influencing the market is included in each of the report's several segments. These elements, known as market dynamics, comprise the opportunities, obstacles, drivers, and constraints that shape the market and define how these elements affect it. The market's potential and challenges are extrinsic, while its drivers and restraints are intrinsic. A revenue forecast for the market's growth over the course of the forecast period is given by the Global Avelumab Market report.
Avelumab Market Trends:
A developing category of cancer treatment is cancer immunotherapy, which includes immune checkpoint inhibitors like avelumab. As immunotherapy shows promise in the fight against a variety of malignancies, this trend is anticipated to continue.
Broadening the Scope of Treatment Applications: Avelumab is now approved for Merkel-cell carcinoma and non-small cell lung carcinoma (NSCLC), but ongoing clinical trials are assessing its effectiveness in other cancer forms as well. The market might grow dramatically if these trials are successful.
Patient-Centered Care: Avelumab's capacity to selectively target particular immune pathways presents an opportunity for customized treatment strategies, which is consistent with the increasing emphasis on patient-centered care.
Avelumab Market Scope Of the Report Market Challenges:
Competitiveness: Rivalry: Avelumab's pricing and market share may be impacted by the existence of alternative immune checkpoint inhibitors.
High Cost: Due to the drug's high cost, some patients may find it difficult to afford or for healthcare systems to pay for avelumab.
Exorbitant Treatment Costs: Avelumab, like many cancer medications, is not cheap. This may restrict patient access, particularly in nations with constrained financial resources for healthcare. Care of Side Effects: Avelumab can have infusion responses and weariness as side effects, however they are usually well tolerated. It is imperative that more study be done on controlling these negative effects.
Safety Concerns: Like many potent medications, avelumab can have detrimental side effects. These can include immunological system issues, exhaustion, lung issues, and infusion responses. Physicians must assess each patient's dangers and potential advantages.
Companies Covered: Avelumab Market:
Merck
Pfizer
Others
Global Avelumab Market Segmentation:
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Avelumab market is projected to growth factors:
Increasing Cancer Rates: An older population, lifestyle choices, and more screening are all contributing contributors to the rising incidence of cancer worldwide. As a result, there is a greater chance that patients will benefit from Avelumab.
Expanding Use of Immunotherapy: The use of Avelumab in immunotherapy is one of the fastest-growing segments of cancer treatment. Avelumab may see an increase in demand as medical professionals and patients become more aware of the possible advantages of immunotherapy.
Extending Treatment Uses: Avelumab's potential application for treating other cancer types is being researched. A larger market for Avelumab would result from additional applications being approved.
Reasons Why You Should Buy This Report:
To gain an in-depth understanding of Avelumab Market
To obtain research-based business decisions and add weight to presentations and marketing strategies
To gain competitive knowledge of leading Avelumab Market players
It gives pin point investigation of changing rivalry elements and keeps you in front of contenders.
It helps in settling on educated business choices by having total bits of knowledge of market and by making inside and out investigation of market sections.
Avelumab Market Conclusion :
Riding the Immunotherapy Wave: The market gains from the increasing acceptance of cancer immunotherapy, a major driver of which is Avelumab. Given that immunotherapy is effective against a variety of malignancies, this trend is probably here to stay.
Broadening the Spectrum of Treatment: There is a great deal of room for market expansion from the ongoing clinical trials examining Avelumab's application in novel cancer kinds. The application and patient base could be greatly expanded if these trials are successful. Opening Up New Treatment Options: Avelumab's usage in experimental cancer types is being studied in ongoing clinical trials, which could lead to significant market expansion. If these trials are successful, the application and patient base could be further expanded. Regulatory Approvals: Avelumab's sales and market reach may be greatly impacted by the extension of its regulatory approvals into new indications or geographical areas.
Market Competition: #Avelumab's pricing and market share may be impacted by rival immunotherapies, conventional cancer treatments, and the introduction of biosimilars.
Contact Us: https://wemarketresearch.com/
0 notes
Text
Retevmo Available Worldwide
Retevmo (selpercatinib) is a targeted therapy approved for treating specific types of cancers, including non-small cell lung cancer, medullary thyroid cancer, and other thyroid cancers. If you are looking to get the best Retevmo price in India, Indian Pharma Network (IPN) is your reliable source. IPN specializes in providing access to high-quality medications at competitive prices. With our extensive network and commitment to patient care, IPN ensures that you receive genuine Retevmo promptly and affordably. We assist in navigating the complexities of pharmaceutical procurement, ensuring you get the best possible deal. For the most competitive price and trustworthy service, Indian pharma network to manage your medication needs effectively and affordably, ensuring uninterrupted access to essential cancer treatments.
Retevmo (selpercatinib) 80 mg capsules are a breakthrough medication used for the treatment of certain cancers. Retevmo 80 mg capsule price in India can vary, but obtaining it at the most reasonable cost is essential. Indian Pharma Network (IPN) specializes in helping patients access Retevmo 80 mg capsules through legal and reliable channels. If Retevmo is not available or not approved in your home country, IPN can assist in procuring this critical therapeutic drug. Our extensive network ensures you receive authentic products, helping manage your treatment effectively. By choosing IPN, you benefit from our expertise in navigating the complexities of international pharmaceutical regulations, ensuring timely and cost-effective access to Retevmo.
Looking for the best price for Retevmo 40 mg capsules in India?
Indian Pharma Network (IPN) has you covered. Retevmo (selpercatinib) is a medication used in the treatment of certain types of non-small cell lung cancer (NSCLC), medullary thyroid cancer, and other tumors with RET gene alterations. At IPN, we understand the importance of accessing high-quality medicinal products at an affordable price. We offer the most competitive Retevmo 40 mg capsule price in India, ensuring you receive the best value for your healthcare needs. Our dedicated team ensures a seamless purchasing experience, providing prompt service and reliable delivery. Trust Indian Pharma Network (IPN) for your pharmaceutical needs and benefit from our commitment to affordability and quality.
Retevmo (selpercatinib) is a targeted therapy used to treat certain types of cancers with specific genetic mutations, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other types of thyroid cancers. Retevmo in India is not yet approved, but the Indian Pharma Network (IPN) can assist you in accessing this essential drug at the most reasonable price. Although it’s not yet available in the Indian market, IPN leverages its extensive network to procure and deliver the drug, ensuring patients receive timely and affordable treatment. IPN's commitment to patient care and affordability makes it a reliable partner for those in need of life-saving medications.
#Retevmo in Bahrain#Retevmo in Kuwait#Retevmo in Iraq#Retevmo in Qatar#Retevmo in Saudi Arabia#Retevmo in United Arab Emirates#Retevmo in Romania#Retevmo in China#Retevmo in Latvia#Retevmo in Brazil#Retevmo in UK#Retevmo in Sri Lanka#Retevmo in Pakistan#Retevmo in Nepal#Retevmo in Maldives#Retevmo in Bhutan#Retevmo in Bangladesh#Retevmo in Afghanistan
1 note
·
View note
Text
0 notes
Text
Meeting the Needs of a Growing Population: The Evolving Global Liquid Biopsy Market
The global liquid biopsy market is positioned for rapid expansion, with an estimated revenue of USD 1,538.3 million in 2023. According to insights from healthcare domain experts, providers in the liquid biopsy sector can anticipate a robust Compound Annual Growth Rate (CAGR) of 21.7% through 2033. By the end of the forecast period, the market is projected to achieve a valuation of USD 10,938.6 million, reflecting significant growth opportunities within the healthcare industry.
Liquid biopsy, a non-invasive diagnostic technique that detects biomarkers and genetic material in bodily fluids, is revolutionizing cancer diagnosis, monitoring, and treatment. This innovative approach offers several advantages over traditional tissue biopsy, including real-time monitoring, early detection of treatment response or resistance, and the ability to capture tumor heterogeneity
Tumor tissue is currently the gold standard for determining the kind and stage of cancer. Important players are attempting to reduce the current obstacles to its utilization in order to increase its potential applications in the future. The feasibility of liquid biopsy techniques for identifying cancer patients’ genetic profiles has also been shown by a number of research. The studies carefully take into account the reactions in order to track the course of treatment and identify any early warning symptoms of therapeutic resistance.
Request Your Detailed Report Sample With Your Work Email : https://www.futuremarketinsights.com/reports/sample/rep-gb-1396
Liquid biopsies have become more common in recent years due to the desire for more personalized treatment options. Since liquid biopsy is widely available and reasonably priced in many labs, particularly in developing countries, its use is growing in popularity. For instance, several labs offer liquid biopsy tests.
“Key players are bringing cost reductions in liquid biopsy tests and partnering with local product distributors to strengthen their network base in target markets. Currently, a trend toward emerging economies has been spotted, as cancer cases are particularly on the rise, and a large population base provides significant opportunities in these markets,” says an FMI analyst.
Key Takeaways from the Liquid Biopsy Market Report
The North America liquid biopsy market is expected to account for a leading share of 50.84%. The United States is predicted to account for 43.8%, enjoying a dominant share in the global and regional markets.
The Europe market is anticipated to acquire a market share of 19.6% in 2023. Germany holds a prominent share in the region. In 2023, the country is predicted to amass a total of 6.6% share in the global market.
In Europe, the United Kingdom is predicted to expand at a robust CAGR of 26.4% through 2033.
In Asia Pacific, China and India display a remarkable percentage of growth, i.e., 29.7% and 24.4%, respectively, through 2033.
CTC (Circulating Tumor Cells) is projected to obtain a significant market share of 56.9% by biomarker type in 2023.
By sample type, blood sample type holds prominence in the liquid biopsy market.
Key Developments by Liquid Biopsy Market Players
QIAGEN N.V. (the Netherlands), in May 2022, introduced a therascreen EGFR Plus RGQ PCR Kit, which is a new in vitro diagnostic test for the analysis of sensitive EGFR mutation.
Guardant Health, Inc., in June 2021, introduced Guardant360 Response test that finds variations in circulating tumor DNA (ctDNA) levels.
Hoffmann-La Roche Ltd. (Switzerland), in October 2020, gained United States FDA approval for the extended claims for cobas EGFR Mutation Test v2 to be deployed as a companion diagnostic for an extensive range of therapies to manage non-small cell lung cancer (NSCLC).
Biocept, Inc., in March 2020, agreed with a California-based Independent Physician Association (IPA) to offer its Target Selector liquid assay services to patients and physicians in the network.
Key Companies Profiled:
BIOCEPT, INC.
Qiagen N.V.
Trovagene, Inc
Janssen Global Services, LLC
MDxHealth SA
Natera, Inc
F. Hoffmann-La Roche Ltd
Silicon Biosystems
Pathway Genomics Corporation
Sysmex Corporation
Others
Key Segments Profiled in the Liquid Biopsy Industry Survey:
By Biomarker Type:
CTCs (Circulating Tumour Cells)
ctNA (Circulating tumor Nucleic Acids)
Exosomes
By Sample Type:
Blood Liquid Biopsy
Urine Liquid Biopsy
Other (Plasma, Saliva, CSF) Liquid Biopsy
By Application Type:
Liquid Biopsy for Lung Cancer
Liquid Biopsy for Gastrointestinal Cancer
Liquid Biopsy for Prostate Cancer
Liquid Biopsy for Breast Cancer
Liquid Biopsy for Colorectal Cancer
Liquid Biopsy for Leukemia
By Region:
North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan
Japan
Middle East and Africa
0 notes